Vemurafenib for BRAF V600-mutant erdheim-chester disease and langerhans cell histiocytosis analysis of data from the histology-independent, phase 2, open-label VE-BASKET study

Eli L. Diamond, Vivek Subbiah, A. Craig Lockhart, Jean Yves Blay, Igor Puzanov, Ian Chau, Noopur S. Raje, Jurgen Wolf, Joseph P. Erinjeri, Jean Torrisi, Mario Lacouture, Elena Elez, Ferran Martínez-Valle, Benjamin Durham, Maria E. Arcila, Gary Ulaner, Omar Abdel-Wahab, Bethany Pitcher, Martina Makrutzki, Todd RiehlJosé Baselga, David M. Hyman

Research output: Contribution to journalArticlepeer-review

132 Scopus citations

Fingerprint

Dive into the research topics of 'Vemurafenib for BRAF V600-mutant erdheim-chester disease and langerhans cell histiocytosis analysis of data from the histology-independent, phase 2, open-label VE-BASKET study'. Together they form a unique fingerprint.

Medicine & Life Sciences